MAM
KDNY

Marquette Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Marquette Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,000
Closed -$845K – 319
2023
Q2 		$845K Hold
22,000
– – 0.21% 32
2023
Q1 		$509K Hold
22,000
– – 0.14% 42
2022
Q4 		$576K Sell
22,000
-10,000
-31% -$222K 0.17% 38
2022
Q3 		$629K Sell
32,000
-6,000
-16% -$120K 0.2% 34
2022
Q2 		$665K Buy
38,000
+2,500
+7% +$39.2K 0.19% 45
2022
Q1 		$581K Buy
35,500
+16,261
+85% +$221K 0.14% 56
2021
Q4 		$314K Hold
19,239
– – 0.07% 76
2021
Q3 		$245K Hold
19,239
– – 0.06% 84
2021
Q2 		$272K Sell
19,239
-6,000
-24% -$96K 0.06% 75
2021
Q1 		$392K Sell
25,239
-156,797
-86% -$2.56M 0.09% 56
2020
Q4 		$2.89M Buy
+182,036
New +$2.75M 0.67% 26
2016
Q1 		– Sell
-70,000
Closed -$9.85M – 90
2015
Q4 		$9.85M Buy
+70,000
New +$9.51M 4.01% 6

Marquette Asset Management's KDNY Position: Q3 2023 in Review

Marquette Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 22,000 shares — an estimated $845K sold.

Marquette Asset Management first reported a position in KDNY in Q4 2015 and held it in 12 quarters. The position peaked at $9.85M in Q4 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Marquette Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Marquette Asset Management sold 22,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $845K.
  • Marquette Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 12 quarters.
  • Marquette Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $9.85M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Marquette Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.